Login / Signup

Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Vicente E TorresArlene B ChapmanOlivier DevuystRon T GansevoortVicente E TorresJennifer LeeMolly E HokeAlvin EstiloOlga Sergeyeva
Published in: Clinical journal of the American Society of Nephrology : CJASN (2020)
Open Label Extension of TEMPO 3:4, NCT02251275.
Keyphrases
  • polycystic kidney disease
  • open label
  • clinical trial
  • phase ii
  • phase ii study
  • phase iii
  • study protocol
  • randomized controlled trial
  • radiation therapy
  • atrial fibrillation
  • locally advanced
  • double blind